Matricelf Ltd. is seeking feedback from the FDA regarding its clinical trial design. The company is currently listed on the Tel Aviv Stock Exchange with plans for a dual listing to support its transition.

The entities involved

• FDA →
  • A facility located in St. George is operating under the standards set by the U.S. Food and Drug Administration (FDA) for supplement manufacturing.15:21
  • A company is seeking definitive data for a pre-NDA meeting with the FDA in Raleigh.14:52
• Tel Aviv Stock Exchange →

  stock exchange located in Tel Aviv, Israel

  • Next Vision successfully completed its Initial Public Offering (IPO) on the Tel Aviv Stock Exchange (TASE).12:04
• Nasdaq →

  American fully electronic stock exchange

  • A company whose CEOs are merging is utilizing both the NYSE and Nasdaq as potential listing venues, with operations spanning Maryland and Pennsylvania.15:45
  • A company seeking to maintain its Nasdaq listing is currently having its board of directors determine the advisability of share consolidation.15:29

Related events

• Capricor Therapeutics is seeking regulatory approval from the FDA for clinical trials and has listed on the Nasdaq stock exchange, with a law firm based in New York City involved.Aug 5
• Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.Sep 22
• Mylan is seeking regulatory approval from the FDA for new products and has listed its stock on the Nasdaq exchange.Sep 2
• FDA issued a partial clinical hold on trials involving Biohaven Ltd. on September 11, 2026.Sep 12
• SynAct Pharma AB is seeking discussion with the FDA regarding the design of its Phase 3 clinical trials.Sep 7